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Abstract: Radiation-induced loss of the hematopoietic stem cell progenitor population compromises
bone marrow regeneration and development of mature blood cells. Failure to rescue bone marrow
functions results in fatal consequences from hematopoietic injury, systemic infections, and sepsis. So
far, bone marrow transplant is the only effective option, which partially minimizes radiation-induced
hematopoietic toxicities. However, a bone marrow transplant will require HLA matching, which
will not be feasible in large casualty settings such as a nuclear accident or an act of terrorism. In this
study we demonstrated that human peripheral blood mononuclear cell-derived myeloid committed
progenitor cells can mitigate radiation-induced bone marrow toxicity and improve survival in mice.
These cells can rescue the recipient’s hematopoietic stem cells from radiation toxicity even when
administered up to 24 h after radiation exposure and can be subjected to allogenic transplant without
GVHD development. Transplanted cells deliver sEVs enriched with regenerative and immunemodulatory paracrine signals to mitigate radiation-induced hematopoietic toxicity. This provides a
natural polypharmacy solution against a complex injury process. In summary, myeloid committed
progenitor cells can be prepared from blood cells as an off-the-shelf alternative to invasive bone
marrow harvesting and can be administered in an allogenic setting to mitigate hematopoietic acute
radiation syndrome.
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Radiological terrorism and nuclear threat are ongoing concerns due to their potential
to cause acute radiation syndrome (ARS) [1,2]. High doses of radiation can cause irreparable harm to the bone marrow, initiating leukopenia and increased risk of infection [3–5].
Granulocyte-colony-stimulating factor (G-CSF), which stimulates the bone marrow to produce granulocytes, is the only FDA-approved drug for protection of radiation-induced
tissue damage, but showed limited efficacy in a non-human primate model [6]. Moreover, it
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is not effective in cases of complete myeloablation and may be associated with thromboembolic events. As such, there is no known strategy of post-exposure therapeutic intervention
to rescue/salvage organs at risk in ARS within days after the radiation event has occurred.
ARS is very much dose-dependent, as evident in multiple organs including skin [7],
the hematopoietic system [8], and the gastrointestinal tract [9]. Bone marrow is one of
the most susceptible tissues for radiation toxicity [10,11]. Bone marrow suppression is
evident even with a sub-lethal dose of radiation [11]. Due to a high rate of self-renewal,
hematopoietic stem cells (HSC) are very sensitive to radiation, which leads to the failure of
bone-marrow [12]. Even with a low dose of whole-body irradiation (1 Gy) to mice there
was reduced engraftment capacity of bone marrow derived cells to about 50% compared
with non-irradiated control bone marrow [13]. Bone marrow suppression by a sub-lethal
irradiation can cause a patient to be immunosuppressed due to a reduced number of
functional blood cells. A high dose of radiation will lead to irreversible bone marrow failure
and eventually to death in the absence of intervention. Transplantation of bone marrow
will partially restore hematopoiesis in lethally irradiated subjects, but it is not feasible to
perform this in large casualty settings. Therefore, there is an unmet need to develop a
countermeasure to mitigate hematopoietic acute radiation syndrome (h-ARS) that can be
applicable in a mass casualty setting even when initiated 24 h after radiation exposure.
Previous studies have reported radiation countermeasures against ARS ranging from
small molecules to growth factors and cytokines [14]. There are several bioengineered
analogs of erythropoietin (Aransep, Epoetin, Epogen, Darbepoetin, and Procrit) that are
commonly used for various hematologic indications. The primary indication of these
agents is for the treatment of severe anemia via stimulation of erythropoiesis following
intense chemotherapy or radiotherapy [15,16]. However, these recombinant agents are still
not approved as a medical countermeasure for use in radiation casualties. Furthermore,
leridistim (a chimeric dual G-CSF and IL-3 receptor agonist), which shows efficacy in
ameliorating severe, radiation-induced neutropenia within large, experimental animals,
despite promising initial results, is still not being developed as a countermeasure [17].
Moreover, considering the complexity of h-ARS, a polypharmacy approach may be a
more suitable option [18]. However, proper design and optimization will be a major
challenge. Cell-based therapy can be considered as a natural polypharmacy solution as it
delivers multiple paracrine signals including cytokines and growth factors [19] critical for
radio-mitigation.
Cell-based therapy has now been extended to stem cell therapy and/or stromal cellbased therapy [20]. However, these approaches are not feasible in an unplanned, large-scale
allogenic setting. Stem/progenitor cell therapy such as mesenchymal stem cells (MSCs)
has been used to mitigate radiation injury [21,22]. Although preclinical evidence suggests
that MSCs developed from bone marrow, adipose-derived cells, or induced pluripotent
stem cells (iPSCs) are promising candidates for regenerative cell therapy, clinical evidence
indicates a clear discrepancy between expected and actual outcomes of MSCs taken from
bench to bedside [23,24]. So far there is no cell-based therapy available to mitigate ARS
when applied beyond 24 h post-irradiation in an allogeneic setting. Autologous cell
transplantation can be an alternative option but is only applicable to first responders
and/or military personnel if their own tissue is bio banked in advance.
In the present study, we demonstrate that human peripheral blood mononuclear
cells derived of a lineage-negative population enriched in myeloid-committed progenitor
cells (hMCPs) can mitigate h-ARS in mice even in an allogenic recipient. hMCPs have
an advantage over bone-marrow-derived MSCs because they can be cultured from blood
obtained via a minimally invasive collection method compared with the painful collection
and tedious isolation and processing of cells from bone marrow. In summary, our studies
demonstrate that hMCP transplantation at 24 h or later can mitigate h-ARS in mice. Extracellular vesicles derived from hMCPs mediate the release of paracrine signals, which play
a significant role in the amelioration of radiation-induced reduction of HSCs, maintaining
bone marrow function and preventing radiation-induced lethality via h-ARS.

Int. J. Mol. Sci. 2022, 23, 5498

which play a significant role in the amelioration of radiation-induced reduction of HSCs,
maintaining bone marrow function and preventing radiation-induced lethality via
3 of 21
h-ARS.
2. Results
Transplantation of hMCP Cells Mitigates h-ARS and Improves Survival
2.2.1.
Results
2.1. Transplantation
of hMCP Cells
Mitigates
h-ARS
Improves
Human PBMC-derived
Lin-CD34+
cells
wereand
cultured
in Survival
myeloid progenitor expansion
medium
to
enrich
Lin-CD45RA-CD34+CD38+
cells
(Figure
1A–C).progenitor
The expanded
Human PBMC-derived Lin-CD34+ cells were cultured in myeloid
expancells
collected
at
day
14
demonstrated
significantly
higher
expression
of mye-cells
sion medium to enrich Lin-CD45RA-CD34+CD38+ cells (Figure 1A–C). The expanded
loid-committed
cell markers;
1.5 fold higher
for CD33
(p < 0.005),of1.5
fold for NRG-3
collected
at day progenitor
14 demonstrated
significantly
expression
myeloid-committed
(p
<
0.05),
and
2.5
fold
for
Tnfrs-11a
(p
<
0.0005)
then
the
cells
collected
at
day
progenitor cell markers; 1.5 fold for CD33 (p < 0.005), 1.5 fold for NRG-3
(p 7<(Figure
0.05), and
1B).
Therefore,
in
all
the
experiments
of
this
study
we
used
cells
collected
after
14
days
of in
2.5 fold for Tnfrs-11a (p < 0.0005) then the cells collected at day 7 (Figure 1B). Therefore,
expansion.
all the experiments of this study we used cells collected after 14 days of expansion.

Figure1.
1. Characterization
Characterization of
myeloid-committed
progenitor
cellscells
(hMCPs).
Figure
ofPBMC-derived
PBMC-derivedhuman
human
myeloid-committed
progenitor
(hMCPs).
(A) Schematic representation of hMCP cells expansion from a frozen vial of PBMC. (B) Fold change
(A) Schematic representation of hMCP cells expansion from a frozen vial of PBMC. (B) Fold change
relative expression of myeloid-committed progenitor cells marker expression between day 7 vs day
14 collected cells. Data are presented as the mean ± SD. (Significance level, *: p < 0.05, **: p < 0.005,
***: p < 0.0005). (C) Flow cytometric characterization of ex vivo expanded cells depicts 98% Lin−cells
population in the single live cells analyzed, which give rise to 68% of Lin−CD45RA−cells being
CD34+ and 61% of Lin−CD45RA−CD34+ cells being CD38+, while the percentage of Cd34+Cd38−
was 6.2%. The phenotypic characterization of Lin−CD45RA−CD34+CD38+ cells expressed myeloid
cell markers: 57% being CD123+ and 51% being CD135/Flt3+.
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To test the potential radio-mitigating effect of hMCPs, immunocompetent C;129S4Rag2tm1.1Flv Il2rgtm1.1Flv /J (Rag2-γc-) mice (n = 25 per group) were exposed to whole-body
irradiation (Figure 2A). First, we exposed Rag2-γc- mice to a dose range of 4–6 Gy where
6 Gy represented LD70/30 dose level. Mice receiving two doses of intravenous cells transfusion (2 × 106 cells/mice/transfusion) at 24 h and 48 h post irradiation demonstrated
significant improvement in survival (4 Gy p < 0.0001; 6 Gy; p < 0.0001) compared with irradiated untreated controls (Figure 2B,D). To validate the radio-mitigating role of hMCPs in a
second strain, immunocompetent NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl /SzJ (NRG) mice (n = 30
per group) were exposed to 7 Gy (LD70/30) and then treated with same dose and schedule
of hMCP cell transfusion. Please note that the radiation dose level was increased to achieve
LD70/30 due to differences in radiosensitivity in NRG mice compared with Rag2-γc mice.
NRG mice receiving cell transfusion demonstrated a significant improvement in survival
compared with irradiated controls (7 Gy; p < 0.0002) (Figure 2F). Mice with hMCP cell
transplantation also demonstrated better restitution of body weight compared with irradiated untreated controls (Figure 2C,E,G). In a separate study, NRG mice receiving a single
dose of hMCP transfusion at 24 h after irradiation also showed significant improvement
in survival (p < 0.024) (n = 12 mice per group) (Supplementary Figure S1) compared with
irradiated controls. As whole-body irradiation with an LD70/30 dose primarily involves
hematopoietic syndrome, our results clearly suggested that PBMC-derived hMCPs can be
considered as potential mitigators against h-ARS.
Optimization of cryopreservation and minimization of cell preparation time are very
important to consider any cell-based therapy for point-of-care treatment against acute
radiation syndrome. In the current study, hMCPs were cryopreserved in CS5 cryopreservation media at liquid nitrogen temperature. Before treatment, cryopreserved hMCPs were
quickly thawed to 37 ◦ C in a water bath followed by incubation with culture media at 37 ◦ C
for 10 h. Mice receiving two doses of this cell preparation (2 × 106 cells/mice/transfusion)
at 24 h and 48 h post irradiation demonstrated a significant improvement in survival
(p < 0.005) (Supplementary Figure S2).
2.2. hMCP Rescues HSCs and Induces Regenerative Potential against Radiation Injury
Radiation-induced loss of HSCs significantly impairs bone marrow regeneration [25,26].
As hMCPs rescued bone marrow and improved survival post-irradiation, we further examined the effect of hMCP transfusion on HSC survival and regenerative function in irradiated
mice [12,27]. Radiation reduced the number of mouse HSCs; however, transplantation of
hMCPs resulted in recovery of mouse HSCs (p < 0.034) (Figure 3A,B). We also detected
the presence of human cells in xenograft-recipient bone marrow even after 28 days post
irradiation (Figure 3C), suggesting their involvement in mouse bone marrow regeneration.
To further validate bone-marrow recovery, we analyzed bone histology in these mice and
found that radiation caused a significant loss of cellularity in bone marrow, which recovered after transplantation of hMCP cells (p < 0.005) (Figure 3D). Analysis of blood shows
that lymphocyte titers were significantly less in the radiation group, which also recovered
after hMCP cell transplantation (p < 0.01) (Figure 3E). These data demonstrate that hMCPs
specifically enhance the recovery of HSCs following irradiation.
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Optimization of cryopreservation and minimization of cell preparation time are very
important to consider any cell-based therapy for point-of-care treatment against acute
radiation syndrome. In the current study, hMCPs were cryopreserved in CS5 cryopreservation media at liquid nitrogen temperature. Before treatment, cryopreserved hMCPs
were quickly thawed to 37 °C in a water bath followed by incubation with culture media
at 37 °C for 10 h. Mice receiving two doses of this cell preparation (2 × 106
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mouse bone marrow regeneration. To further validate bone-marrow recovery, we analyzed bone histology in these mice and found that radiation caused a significant loss of
cellularity in bone marrow, which recovered after transplantation of hMCP cells (p <
0.005) (Figure 3D). Analysis of blood shows that lymphocyte titers were significantly less
in the radiation group, which also recovered after hMCP cell transplantation (p < 0.01)
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HSCs following irradiation.
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tion injury. (A) Schematic representation of the experimental plan (radiation dose and timeline for
cells transplantation). (B) Recovery of mouse bone-marrow HSCs after hMCP transplantation in comparison with the IR group (p < 0.05) (C) Presence of transplanted human cells in mouse bone-marrow
after four weeks of transplantation, identified using CD45 marker expression (D) Histopathological
analysis with cell counts of bone-marrow shows the recovery of bone-marrow after hMCP transplantation compared with the IR group (p < 0.005) (E) Blood analysis revealed that the lymphocyte
concentration was significantly improved in the IR + hMCP group compared with IR alone (p < 0.05).
No IR group represented by hollow circle, IR group represented by filled circle, IR + hMCP group
represented by triangle. Data are presented as the mean ± SD. (Significance level, *: p < 0.05,
**: p < 0.005).

2.3. hMCPs Are Suitable for Allogenic Transplant
To examine the immune-modulatory function of hMCPs, we developed a co-culture
system containing human PBMC, T cells activation beads with/without hMCP cells
(Figure 4A). Presence of hMCPs significantly suppressed the expression of TNFα and
IFNγ in CD4+ and CD8+ T cell populations. Presence of hMCP reduced the expression
of TNFα (PBMC: 1 ± 0.03 fold vs PBMC + hMCP: 0.48 ± 0.09 fold, p < 0.0005) and IFNγ
was (PBMC: 1 ± 0.02 fold vs PBMC + hMCP: 0.76 ± 0.02 fold, p < 0.0005) in CD4 T cells
(Figure 4B,C). A similar observation was made in CD8a+ T cells where hMCPs suppressed
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the expression of TNFα (PBMC: 1 ± 0.26 fold vs PBMC + hMCP: 0.64 ± 0.10 fold, p < 0.005)
and IFNγ (PBMC: 1 ± 0.03 fold vs PBMC + hMCP: 0.87 ± 0.03 fold, p < 0.005) in CD8a T
cells (Figure 4B,D). We did not observe a significant change in the expression of the T cell
marker CD25 in either the CD4 or CD8a T cell populations. These results suggest that the
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Next, we examined whether hMCP can be transplanted in an allogenic setting without
triggering a GVHD-like symptom. hMCPs were transplanted into non-immunocompetent
FVB mice. FVB mice receiving the hMCP transplant did not show any GVHD-like symptoms such as weight loss, hunched posture, or hair loss (Figure 4E,F). The survival study of
irradiated mice receiving hMCPs demonstrated 80% survival as compared with the 30%
survival in the control irradiated group (p < 0.043) with no sign of GVHD until end of the
study (Figure 4G), while no significant changes in body weight of the mice in either group
was observed (Figure 4H).
The peripheral blood and splenic cell analysis of the FVB mice receiving hMCPs did
not demonstrate any immune activation (Figure 5A). In fact, hMCP cells transplantation
significantly suppressed CD8+ (p < 0.05) and Naïve T cells (p < 0.05) subpopulation in the
spleen (Figure 5B), and naïve T cell subpopulation in peripheral blood samples (p < 0.02)
(Figure 5B). No significant change was observed in other analyzed T cell subpopulations
(Central memory T cells, Tregs and Effector T cells) in spleen in response to hMCP treatment
(Figure 5B). This further confirms that the immunosuppressive function of hMCP cells
makes them suitable for allogenic cell transplantation.
GVHDs induces significant pathological changes in organs like skin, liver, and colon [28,29].
In response to hMCP transplant, absence of any GVHD-related tissue damage was confirmed
by histopathological analysis of skin, liver, and colon. hMCP transplant did not induce any
vacuolization in the epidermal region in the skin (Figure 5C(i,ii)). Analysis of liver sections in
hMCP-treated mice did not show any damage or change in immune cell infiltration compared
to irradiated mice receiving no cell transplant (Figure 5C(iii,iv)). Mice with hMCP transplant
did not show any cryptal abscess and necrosis in colon, a typical pathology commonly observed
in GVHD (Figure 5C(v,vi)). The absence of any evidence for GVHD indicated that hMCPs are
suitable for allogenic cell transplantation.
2.4. hMCP-Derived Paracrine Signals Are Enriched with Exosomal Proteins
Our previous reports as well as reports from other groups suggested that following
intravenous transplantation, cells are initially docked in the lung [30–32]. Therefore, the
radio-mitigating function of these cells to the distant injury site such as bone marrow was
primarily dependent on cell-derived paracrine signals. As we observe that transfused
hMCPs primarily lodged in lung and bone marrow (Supplementary Figure S3), it is very
possible that hMCP-derived paracrine signals play an important role in rescue of recipient
mHSCs. We performed a proteomics analysis of hMCP-conditioned medium to determine
paracrine signals. Out of a total of 1447 identified proteins, a significant presence of exosomal proteins (315) (Supplementary Figure S4 and Supplementary Table S2a,b) was observed.
The majority of these proteins are involved in the regulation of biological functions such as
cell metabolic process, regulation of biological process, cell organization, cell growth, and
transport, which are important for regenerative processes, further suggesting possible the
involvement of exosomal cargo for the radiomitigating role of hMCPs.
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GVHDs induces significant pathological changes in organs like skin, liver, and colon
[28,29]. In response to hMCP transplant, absence of any GVHD-related tissue damage
was confirmed by histopathological analysis of skin, liver, and colon. hMCP transplant
did not induce any vacuolization in the epidermal region in the skin (Figure 5C(i,ii)).
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2.5. hMCP-Derived sEVs Mitigates h-ARS
EVs are one of the major carriers of cell-derived paracrine signals including nucleotides
and proteins [33,34]. Due to enrichment in cell-derived cargos and efficient transport to
target tissues due to their smaller size, EV-based therapies are now being prioritized as an
alternative to cell transplantation [35]. In the present study, our proteomics data demonstrated that hMCP-conditioned media are enriched with exosomal protein (Figure 6A).
To validate the involvement of EVs as a major carrier of hMCP-derived paracrine signals,
we examined the radio-mitigating role of EVs in h-ARS. Considering the different types
of extracellular vesicles with variable particle size, we validated the hMCP-derived EVs
populations based on surface marker and particle size. We demonstrated that hMCPderived extracellular vesicle particle sizes are primarily representing small EVs (sEVs) with
modal range particle sizes of 132–148 nm [36,37]. sEVs counts were maintained even after
a freeze–thaw cycle for over 72 h (Figure 6B,C). For subsequent experiment, cryopreserved
exosomes were thawed prior to use. The flowcytometric analysis of purified sEVs demonstrated the presence of common exosomal surface markers expression of CD81 (85.2%),
CD63 (74.7%), and CD9 (31.9%) (Figure 6D). Mice exposed to Whole Body Irradiation with
7.5 Gy were treated with purified sEVs at 24 h and 48 h post-irradiation (200 µg of sEVs
per mouse at each time) by tail vein injection; 62.5% of mice receiving sEVs treatment
survived beyond 30 days post-irradiation as compared with the 25% survival in the control
irradiated group (p < 0.02). The body weight of the mice also showed less weight loss
in the sEVs-treatment group compared with the untreated, irradiated mice (Figure 6E).
Histological analysis of bone-marrow demonstrated damage of the cellular content in
the irradiated group, which recovers in mice receiving hMCP sEVs treatment (Figure 6F).
The total cell counts also showed recovery in the bone-marrow cell number after sEVs
treatment (p < 0.0005) (Figure 6G). These data confirm that the hMCP-derived sEVs carry
the important regenerative factor(s) which mitigate h-ARS.
2.6. hMCP sEVs Promote Regenerative Response of HSCs
To determine the regenerative effect of hMCP-derived sEVs in HSCs, a CFU assay was
performed using CD34+ HSCs. CD34+ cells were exposed to 6 Gy of radiation and incubated with/without hMCP-derived sEVs. Cellular colonies representing colony forming
unit–granulocyte, macrophage (CFU-GM) and burst forming unit–erythroid (BFU-E) were
quantified at 14 days post-treatment. Presence of all these colonies in higher numbers was
noted in irradiated cohorts receiving sEVs compared with irradiated controls (CFU-GM:
IR + sEVs vs. IR, 95 vs. 0.0) (p < 0.0005) (BFU-E: IR + sEVs vs. IR, 95 vs. 47) (p < 0.0005)
(Figure 6H). These results suggest that hMCP-derived sEVs carry important cargo to maintain the stemness of the irradiated HSCs. Therefore, hMCP-derived sEVs can also be an
alternate therapeutic approach to mitigate radiation-induced injury.
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2.7. hMCP-Derived sEVs miRNAs-Associated Regenerative and Immune-Modulatory Process
The sEVs miRNAs have properties to alter the biological pathways involved in cellular
homeostasis, repair and regeneration, immunomodulation, etc. [38]. It is reported that
miRNAs present in the sEVs can influence target cell function [39,40]. hMCP sEVs analysis
identified miRNAs associated with HSC proliferation, regeneration, homeostasis, and
differentiation (Table 1 and Supplementary Figures S5–S11). Moreover, these sEVs also
carry immunomodulatory miRNAs as well. The GO analysis also identified different molecular functions such as protein binding, RNA binding, RNA polymerase binding, enzyme
regulator activity, etc. being modulated by exosomal miRNA. Further, the KEGG analysis
was used to predict the target signaling pathway for HSCs proliferation, regeneration, and
differentiation being regulated by hMCP sEVs miRNA. Various signaling pathways related
to bone marrow regeneration were identified such as the TGF-β signaling pathway [41],
PI3K-Akt signaling pathway [42], chemokine signaling pathway [43], Hedgehog signaling
pathway [44], Wnt signaling pathway [45], FoxO signaling pathway [46], etc. (Supplementary Figure S12–S15). Although further mechanistic and validation study is needed, our
current observations clearly shed light on the hMCP paracrine activity responsible for the
tissue-specific regenerative properties of hMCPs.
Table 1. Small extracellular vesicles (sEVs)-miRNA involved in various biological functions of
Hematopoietic Stem Cells including proliferation, homeostasis, cell lineage, differentiation, and
regulation of differentiation using their target genes.
Identified miRNA

p-Value

Counts

Target Genes

Hematopoietic Stem Cell Proliferation
hsa-miR-22-3p
hsa-miR-148a-3p
hsa-miR-1246

0.007
0.017
0.029

52
11
2038

hsa-miR-19b-3p

0.012

69

hsa-miR-495-3p

0.033

11

hsa-miR-765

0.040

83

hsa-miR-582-5p

0.004

12

hsa-miR-1915-3p

0.018

613

hsa-miR-570-3p

0.031

11

hsa-miR-148b-3p

0.034

18

hsa-miR-4516

0.046

2637

Identified miRNA

p-Value

Counts

CTC1, MECOM, WNT1
WNT1, WNT10B, WNT2B
CTC1, PIM1
ARIH2, ATXN1L, CD34, EIF2AK2, MECOM, N4BP2L2, SFRP2, THPO,
WNT1, WNT2B
ACE, ARIH2, ATXN1L, CTC1, EIF2AK2, MECOM, N4BP2L2, NKAP,
RUNX1, SFRP2, WNT2B
ACE, ARIH2, ATXN1L, CD34, EIF2AK2, ETV6, NKAP, PIM1, RUNX1,
WNT1, WNT10B, WNT2B
ACE, ARIH2, ATXN1L, CTC1, EIF2AK2, MECOM, N4BP2L2, NKAP,
PDCD2, PIM1, RUNX1, SFRP2, THPO, WNT1, WNT10B, WNT2B
ACE, ARIH2, ATXN1L, CD34, CTC1, EIF2AK2, ETV6, N4BP2L2, NKAP,
PDCD2, PIM1, RUNX1, SFRP2, THPO, WNT1, WNT10B, WNT2B
ARIH2, ATXN1L, CD34, CTC1, EIF2AK2, ETV6, MECOM, N4BP2L2, NKAP,
PDCD2, PIM1, RUNX1, SFRP2, WNT1, WNT10B, WNT2B
ACE, ARIH2, ATXN1L, CTC1, EIF2AK2, ETV6, MECOM, N4BP2L2, PDCD2,
RUNX1, THPO, WNT1, WNT10B, WNT2B
ACE, ARIH2, ATXN1L, CD34, CTC1, EIF2AK2, ETV6, N4BP2L2, NKAP,
PDCD2, PIM1, RUNX1, THPO, WNT1, WNT10B, WNT2B
Target Genes

Hematopoietic Stem Cell Homeostasis
hsa-miR-130a-3p

0.044

13

CCN3, NLE1, TCIRG1, UBAP2L
Hematopoietic Cell Lineage

hsa-miR-451a
hsa-miR-34a-5p
hsa-miR-148b-3p
hsa-miR-34a-5p
hsa-miR-451a

0.010
0.013
0.022
0.031
0.035

10
16
18
16
10

IL6, IL6R
CD24, CD44, CSF1R, IL6R, ITGA6, ITGB3, KIT, TFRC, TNF
CSF1, ITGA5
CD24, CD44, CSF1R, IL6R, KIT
IL6, IL6R
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Table 1. Cont.
Hematopoietic Stem Cell Differentiation
hsa-miR-223-3p
hsa-miR-146a-5p
hsa-miR-184
hsa-miR-34a-5p
hsa-miR-223-3p
hsa-miR-155-5p
hsa-miR-34a-5p

0.007
0.008
0.020
0.028
0.041
0.044
0.047

46
66
24
16
46
268
16

IL6, LMO2, STAT5A
CXCR4, FOS, IL6, NOTCH1
CSF1, NFATC2
FOS, KCNH2, LEF1, MYB, NOTCH1
IL6, LMO2, STAT5A
FLI1, FOS, IL6, MXI1, MYB, SPI1, THRB
FOS, ITGB3, KCNH2, LEF1, MYB, NOTCH1

Regulation of Hematopoietic Stem Cell Differentiation
hsa-miR-615-3p

0.048

13

hsa-miR-105-5p

0.018

17

CBFB, CDK6, HSPA9, PSMB7, PSMD13, PSMD2, PSMD8, PSMF1, TCF3,
YTHDF2
CDK6, MYB

3. Discussion
The present study addressed a gap in cell-based therapy to mitigate H-ARS. Efforts
have been made to use cell replacement therapy to ameliorate radiation-induced bone
marrow syndrome and multiple sources such as bone marrow or adipose tissue have
been recognized to develop MSCs or HSCs as major candidates for cell-based therapy [47].
However, several logistical issues, such as harvesting the cells through invasive approaches,
recovery of cryopreserved cells, and HLA testing to avoid graft vs host disease, limit
the potential of these candidates as radiation countermeasures in mass casualty settings.
MSCs developed from bone marrow or adipose tissue or induced pluripotent stem cells
(iPSCs) are promising candidates for regenerative cell therapy; however, clinical evidence
indicates a clear discrepancy between expected and actual outcomes of MSCs taken from
bench to bedside [23,24]. Therefore, an alternative cell candidate is needed for radiation
countermeasure efforts. In the present study, we showed that hMCPs can overcome all the
major challenges of cell-based therapy against acute radiation syndrome. hMCPs developed
from human blood PBMCs are prepared from peripheral blood that can be drawn from the
donor multiple times non-invasively, vs harvesting by biopsy of the hip or sternum. After
expansion, these cells can be stored and recovered even from a cryopreserved state without
compromising any functional efficacy. Moreover, hMCPs did not show any GVHD when
transplanted in an allogenic setting.
Mice exposed to whole-body irradiation with LD70/30 doses showed improvement in
overall survival when treated with hMCPs at 24 h after irradiation. Histopathological and
flowcytometric analysis clearly demonstrated the radiation-induced loss of bone marrow
cells but recovery with the hMCP transplant. Significant recovery of recipient mice HSCs
with hMCP transplant along with improvement in blood lymphocyte count suggested
recovery of hematopoietic regeneration. Moreover, the presence of transplanted hMCPs
was also noted in these mice even after 28 days of transfusion, suggesting the strong
potential of hMCPs for cell-replacement therapy.
One of the major concerns of cell transplant in the allogenic setting is immunologic
graft rejection by the host’s immune system. Presence of allogenic cells can activate alloreactive T cells through antigen-presenting cells (APCs). Expanded allo-reactive T cells can
infiltrate and damage target tissues. hMCPs have shown systemic immuno-suppressive
function when transplanted in allogenic mice and mitigate h-ARS without inducing any
GVHD in allogenic mice even in later stages (>30 days) post-irradiation. Clinical GVHD has
an acute form which may damage the skin, liver, and gastrointestinal tract. Our data clearly
showed that hMCP transplant did not promote any acute toxicity in allogenic recipient
mice, suggesting the inhibition of GVHD. However, further studies are required to examine
the effect hMCP treatment against delayed effect of acute radiation syndrome along with
any chronic GVHD symptom.
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Recovery of host HSCs and rapid compensation of their functions are critical for bone
marrow regeneration and mitigation of h-ARS. While donor progenitor cells can lodge,
engraft, and proliferate to repopulate the bone marrow, restitution of host HSCs at early
time points post-irradiation can only be achieved by donor cell-derived paracrine signals.
Our flowcytometry data clearly showed that mHSCs are also rescued in transplanted mice,
suggesting restitution of repair and regeneration of the host HSC population. However,
this can only happen through donor cell-derived paracrine signals as transplanted hMCPs
are initially lodged into lung. sEVs are the major carrier of cell-derived paracrine signals
including regenerative signals, anti-inflammatory signals, anti-oxidative signals in the
form of proteins, lipids, and nucleic acids. Our proteomics and sEVs miRNA analysis
also demonstrated the presence of exosomal cargo related to the BM regenerative process.
Mitigation of h-ARS with hMCP-derived sEVs treatment further confirmed the involvement
of paracrine signals in inducing host BM regeneration. Finally, sEVs showing radiomitigation efficacy were previously cryopreserved and therefore can be considered for a
national stockpile.
Acute radiation syndrome is a complex disease process that may lead to multi-organ
syndrome. In recent years, polypharmacy approaches have been gaining more attention
over single-agent treatment against such complex multi organ or systemic injury. While
identification and optimization of polypharmacy is a challenge, cell, or sEVs-based therapy
can perform as an efficient natural polypharmacy as it delivers multiple physiological
factors through paracrine signals [48]. Therefore, cell or exosomal treatment enriched with
multiple regenerative and immunomodulatory factors should be considered as a leading
radio-mitigation approach.
4. Materials and Methods
4.1. Human Myeloid-Committed Progenitor Cell (hMCP) Culture
Human myeloid progenitor cells were cultured from human PBMCs purchased from
StemCell Technologies (Cat no. 70025.3) and plated in T75 flasks. After 24 h of incubation,
cells were transferred to a fresh flask and cultured for seven days with expansion media
containing StemSpan™-XF with addition of StemSpan™ CD34+ Expansion Supplement
(StemCell Technology, Vancouver, BC, Canada). Cells were collected after 14 days of
expansion and characterized by flowcytometry analysis.
4.2. Characterization of hMCP
Expanded cells were characterized for myeloid-committed progenitor cell expression
markers. During cell expansion, cells were collected on day 7 and day 14 and analyzed for
expression of myeloid-committed progenitor cell genes (CD33, NRG-3, Tnfrs-11a) [49–51]
by qPCR. RNA was extracted from day 7 and 14 expanded cells using RNeasy Mini Kit
(Qiagen, Germantown, MD, USA). The concentration and purity of the extracted RNA
were checked using a NanoDrop spectrometer (Thermo Scientific, Waltham, MA, USA).
1 µg of total RNA was reverse-transcribed using RNA to cDNA EcoDry™ Premix (Double
Primed) (Takara Bio USA Inc., San Jose, CA, USA). The reaction mixture was incubated
for 1 h at 42 ◦ C; incubation was stopped at 70 ◦ C for 10 min. Quantitative real-time PCR
(qPCR) was performed using the QuantStudio™ 7 Flex Real-Time PCR System (Applied
Biosystems™, New York, NY, USA) and SYBR Green Supermix (Bio-Rad, Hercules, CA,
USA) with specific primers to the target genes in a 20 µL final reaction volume. The primer
sequences are listed in Supplementary Table S1. Beta-actin was used as a reference gene
for sample normalization. The delta-delta threshold cycle (∆∆Ct) method was used to
calculate the fold change expression in mRNA level in the samples.
Further, the phenotype of the expanded cells was characterized by flowcytometric
analysis using the following antibodies: BV605 CD34 (Clone 581, BioLegend, San Diego, CA,
USA), BV711 CD45RA (Clone HI100, BD Biosciences), BV510 Lineage (BioLegend, 348807),
APC CD38 (Clone REA 572, MACS), PE CD123 (Clone AC145, MACS), PE/Cy7 CD135
(Clone BV10A4H2, BioLegend) [52]. According to previous reports, myeloid-committed
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progenitors are Lin-CD45RA-CD34+CD38+ cells with the highest myeloid colony forming efficiency compared with Lin-CD45RA-CD34+CD38− cells [53]. The percentage of
Lin-CD45RA-CD34+CD38+ cells was measured in the total cell population. Further, the percentage of Lin-CD45RA-CD34+CD38+ cells expressing the myeloid-committed cell markers
CD123, CD135/Flt3 was measured to determine hMCP cell population. We did not observe
any significant difference in surface markers in hMCPs derived from different batches
of PBMC. The flowcytometry data were analyzed by FlowJo software (BD Biosciences,
Franklin Lakes, NJ, USA).
4.3. Collection of hMCP-Conditioned Media
For collection of hMCP-conditioned media, cells were cultured at a density of 16–18 × 103
cells per cm2 in T175 cm2 flasks with 20 mL of cell expansion media. After 4 days of expansion,
cells were washed with PBS two to three times followed by a final wash with supplement
free Basal media for complete removal of cell expansion medium and antibiotics. Over
the next 24 h these hMCPs (52 × 103 cells per cm2 ) were incubated with supplement-free
Basal media. After 24 h, conditioned media were collected for further in vivo and in vitro
applications. Cells incubated over 24 h without growth supplement showed 82.4% viability
with the concentration of 42.8 × 103 cells per cm2 . Conditioned media collected from different
flasks from passage 4 and 5 pooled together and centrifuged at 500× g for 10 min at 4 ◦ C to
remove the cells. Cell-free conditioned media was frozen at −80 ◦ C until further use.
4.4. Isolation of Small Extracellular Vesicles (sEVs) from hMCP-Conditioned Media
sEVs were isolated from hMCP-conditioned media using a differential centrifugation
method as described previously [54]. A detailed schematic diagram for sEVs isolation from
hMCP-conditioned media using the Ultracentrifugation method is described in Supplementary Figure S16. In brief, the conditioned media from hMCP cells was centrifuged at 500× g
for 10 min at 4 ◦ C to remove the cells. The supernatant was centrifuged at 2000× g for
10 min at 4 ◦ C to remove any leftover dead cells. To remove the apoptotic bodies/debris,
the supernatant was centrifuged at 10,000× g for 30 min at 4 ◦ C. The supernatant was then
subjected to ultracentrifugation at 100,000× g for 70 min at 4 ◦ C. The pellet-containing sEVs
were washed with cold PBS at 100,000× g for 70 min at 4 ◦ C. The sEVs exosome pellet was
resuspended in PBS and stored at −80 ◦ C for further studies.
4.5. Characterization of sEVs
sEVs were characterized by flowcytometry by using FITC CD9 (clone HI9a, BioLegend), Pe CD81 (clone 5A6, BioLegend), APC CD63 (clone H5C6, BioLegend) antibody
cocktail in 30 µL of suspension and incubated 20 min at 4 ◦ C in the dark. After incubation, the sEVs were washed twice with PBS and transferred to the flowcytometry tube for
analysis. Flowcytometric data were analyzed by FlowJo software.
4.6. sEVs Protein Estimation and Particle Count
The total protein concentration of isolated sEVs was determined using the micro
bicinchoninic acid (BCA) assay kit (Thermo Scientific, Waltham, MA, USA) according
to the manufacturer’s instructions. Briefly, the isolated sEVs were diluted 1:80 using
distilled water and 150 µL of a BCA mixture of reagent A, B, and C (A:B:C = 25:24:1)
was added and incubated for 2 h at 37 ◦ C. The optical density (OD) of the sample was
measured at 562 nm on the Infinite 200 PRO multimode plate reader (Tecan Group Ltd.,
Männedorf, Switzerland). The protein concentration was calculated from a standard BCA
curve. All measurements were carried out under constant experimental conditions to
obtain comparable results.
4.7. Nanoparticle Tracking Analysis (NTA) of sEVs
Size distribution and concentration of isolated sEVs were measured by Nanosight
NTA (LM10, Malvern Inst. Ltd., Malvern, UK). The NTA analyzes the motion of particles
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illuminated by a laser, from which it deduces their size and concentration. sEVs samples
were diluted (1:10) with PBS and readings were taken in triplicates.
4.8. Exosomal miRNA Analysis
Purified sEVs were subjected to RNA isolation using the exoRNeasy kit (QIAGEN,
USA) according to the manufacturer’s protocol. Quality of the isolated EV-derived RNA
was assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies Inc., Santa Clara,
CA, USA). The Nano String nCounter miRNA expression assay was then used to measure
the levels of ~800 miRNAs following the manufacturer’s protocol. This assay provides a
direct, digital count of each miRNA without the use of reverse transcription or PCR-based
amplification. Briefly, 50 ng of the EV-derived RNA was used for the assay. Following
overnight hybridization at 65 ◦ C with the Reporter Code Set and Capture ProbeSet, the
samples were further processed on the automatic Prep Station to remove excess reporter
probes and non-target cellular transcripts followed by removal of excess capture probes.
The purified target/probe complexes were then immobilized on the cartridge for data
collection via digital imaging on the Digital Analyzer. Barcode counts were tabulated in
a comma separated value (CSV) format and analyzed using the nSolver™ software (ver.
3.0) to assess data quality and perform data normalization using the Top 100 normalization
method built into the software. Normalized miRNA data obtained from these assays were
analyzed using miRNA database online software miRPathDB 2.0 (https://mpd.bioinf.unisb.de/overview.html) accessed on 12 August 2021 to predict their related function and
target genes. From the total number of miRNAs identified, a cutoff was made based on
count number from the Nano String assay. MicroRNAs with a count number >10 were
further analyzed using Gene Ontology (GO) annotation and Kyoto Encyclopedia of Genes
and Genomes (KEGG) pathway analysis.
4.9. T Cells Inhibition Assay
To confirm the immunosuppressive capacity of cultured hMCPs, we performed T cell
inhibition assays as described previously using the suppressive role of mesenchymal stem
cells [55]. The cultured hMCPs were plated at a density of 1 X 105 cells per well of 24 well
plates along with 1 × 106 PBMCs with 25 µL of T Cell-activating beads (ImmunoCult™
Human CD3/CD28 T Cell Activator Cat no 10970, StemCell Technology) per mL of media.
The culture was incubated at 37 ◦ C with 5% CO2 for 72 h. After incubation, the secretion of
proinflammatory cytokines (IFN-γ and TNF-α) and surface marker (CD25) of T cells were
analyzed by flowcytometric analysis.
4.10. Mice
10–12 week old male NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl /SzJ (NRG mice) (Stock #7799,
Jackson laboratories, Bar Harbor, ME, USA) and 10–12 week old male C;129S4-Rag2tm1.1Flv
Il2rgtm1.1Flv /J (Rag2-γc-mice) (Stock #014593, Jackson laboratories) immunocompromised
mice were used in the present study. Both these immunocompromised mice do not have
the Prkdc mutation, which makes them a less radiosensitive strain compared with other
immunocompromised mice for the use of cells engraftment studies. However, there
are moderate differences in radiosensitivity between these two strains. To examine the
efficacy of hMCP transplantation in an allogenic setting, we used 8–10 week old nonimmunocompromised male FVB mice (Stock#01800, Jackson laboratories). All of the
experimental mice were maintained in a pathogen-free environment and housed in cages
in groups of five animals per cage with constant temperature and humidity and a 12 h/12 h
light/dark cycle. All animals always had access to food (8604; Teklad Rodent Diet) and
water. All of these animal studies were performed under the guidelines and protocols of
the Institutional Animal Care and Use Committee of the University of Kansas Medical
Center (ACUP number 2019-2487).

Int. J. Mol. Sci. 2022, 23, 5498

17 of 21

4.11. Irradiation
An irradiation procedure was performed on mice anesthetized with 87.5 mg/kg of Ketamine and 12.5 mg/kg of Xylazine using a small animal radiation research platform (XENX;
XStrahl, Suwanee, GA, USA) as previously described [56] at a dose rate of 2.26 Gy/min at
220 V and 13 mA. To ensure homogeneous dose delivery, half of the dose was delivered
from the anterior–posterior direction and the other half from the posterior–anterior direction. The output of the X-ray irradiator was verified using an ion chamber measurement
detector system to confirm the dose rate of the irradiator. Based on the calculated dose
and the dose rate, the time of irradiation was calculated to meet the required radiation
dose. Dosimetry was routinely performed by a physicist from the Department of Radiation
Oncology, University of Kansas Medical Center, Kansas City, KS, 66160, USA.
4.12. Assessment of Graft Vs Host Disease (GVHD)
FVB mice treated with/without hMCPs were monitored daily from day 1 until day
14 for the clinical manifestations of GVHD (for example, weight loss, hunched posture,
poor activity, ruffled fur) [57]. After 14 days, animals were euthanized and blood and
spleen were collected for immune cell analysis while skin, liver, and colon were collected
for histological analysis of GVHD assessment.
4.13. Bone Marrow Cell Analysis
Cells were harvested from femurs and tibias. Red blood cells were lysed using 0.16 M
ammonium chloride. Cells were stained using the following antibodies: FITC lineage,
BioLegend (CD3e, clone 145-2C11, CD4, clone GK1.5, CD8a, clone 53-6.7, B220, IgM,
clone RMM-1, Mac-1, clone M1/70, Gr1, clone RB6-8C5, Ter119 respectively); PE-Cy7
Sca-1 (clone D7, BioLegend); APC c-Kit (clone ACK2, BioLegend; BV711 CD150 (clone
TC15-12F12.2, BioLegend); PerCP Cy5.5 CD48 (clone HM48-1, BioLegend); BV421 human
CD45 (clone HI30, BioLegend) [58]. Flow cytometry analysis was performed using a
custom LSR Fortessa X-20 analyzer (BD Biosciences). Data analysis was performed using
FlowJo software (BD Biosciences). Mouse HSCs were defined as lineage negative, Sca-1+,
c-Kit+, CD150+, CD48− cells. Cellularity was based on the total nucleated cell count from
1 femur + 1 tibia.
4.14. Histology of Bone Marrow
Bones were fixed in 10% neutral-buffered formalin (G Biosciences) followed by decalcification. After decalcification, bones were processed for paraffin embedding. Then, 5 µm
sections were cut and placed on the slides for hematoxylin and eosin (H&E) staining. The
H&E slides from all the groups were examined by light microscopy to capture bright-field
images using EVOS XL core microscope.
4.15. Ex Vivo Colony-Forming Unit (CFU) Assay
Human Bone-marrow derived CD34+ cells were kindly gifted by Ossium Health
(Indianapolis, IN, USA) for performing CFU assay. Cells were plated in 96-well plate
with StemMACS HSC-CFU assay media (Miltenyi Biotec Inc., Auburn, CA, USA) and
cultured for 14 days according to the manufacturer’s protocol. All of the plates were
incubated at 37 ◦ C with 5% CO2 for 14 days. After incubation, colonies were stained with a
staining cocktail of fluorochrome-conjugated antibodies: CD235a antibody, anti-human,
PE, REAfinity™ (clone: REA175, isotype: recombinant human IgG1), CD15 antibody, antihuman, APC (clone: VIMC6, isotype: mouse IgM), CD14 antibody, anti-human, VioBlue®
(clone: TÜK4, isotype: mouse IgG2aκ) as per the manufacturer’s protocol and subjected to
flowcytometric analysis.
4.16. Proteomics Analysis of hMCP-Conditioned Media
Conditioned media from expanded hMCPs were collected and centrifuged at 500× g
for 10 min to remove any cell debris. Supernatants were stored at −80 ◦ C until they were
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sent to BGI Global genomic services, San Jose, USA for mass spectrophotometry. Growth
medium used for cell culture were considered as background control. All the MS data were
further analyzed using Ingenuity Pathway Array assist software.
4.17. Statistical Analysis
A comparison between groups was carried out by nonparametric T-test (Mann–
Whitney test) using GraphPad Prism 9 (GraphPad Software, San Diego, CA, USA). Kaplan–
Meier Survival analysis of mice survival/mortality in different treatment groups was
analyzed by Kaplan–Meier (Mantel–Cox) as a function of radiation dose using GraphPad
Prism. All data are presented as mean ± standard deviation (SD). A difference between
groups with * p < 0.05, ** p < 0.005, or *** p < 0.0005 was considered statistically significant.
5. Conclusions
This study established hMCPs as a major therapeutic candidate to mitigate h-ARS.
These cells can be transplanted to allogenic recipients, suggesting their applicability in
mass casualty settings. Moreover, our data clearly suggest that hMCPs mitigates h-ARS by
inducing repair and regeneration of host HSCs as well as repopulating the bone marrow
by self-renewal and proliferation. We were able to identify several proteins and miRNAs
responsible for the activation of regenerative process. hMCP should be considered as a
major candidate for polypharmacy against h-ARS. To advance our cell-based therapy for
clinical applications, further studies are needed in large animal models where hMCPs will
be tested in combination with existing standard-of-care treatments against h-ARS.
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